BACKGROUND: Tick transmission of Borrelia spirochetes to humans results in significant morbidity from Lyme disease worldwide. Serum concentrations of antibodies against outer surface protein A (OspA) were shown to correlate with protection from infection with Borrelia burgdorferi, the primary cause of Lyme disease in the United States. METHODS: Mice transgenic for human immunoglobulin genes were immunized with OspA from B. burgdorferi to generate human monoclonal antibodies (HuMabs) against OspA. HuMabs were generated and tested in in vitro borreliacidal assays and animal protection assays. RESULTS: Nearly 100 unique OspA-specific HuMabs were generated, and 4 HuMabs (221-7, 857-2, 319-44, and 212-55) were selected as lead candidates on the basis of borreliacidal activity. HuMabs 319-44, 857-2, and 212-55 were borreliacidal against 1 or 2 Borrelia genospecies, whereas 221-7 was borreliacidal (half maximal inhibitory concentration, < 1 nM) against B. burgdorferi, Borrelia afzelii, and Borrelia garinii, the 3 main genospecies endemic in the United States, Europe, and Asia. All 4 HuMabs completely protected mice from infection at 10 mg/kg in a murine model of tick-mediated transmission of B. burgdorferi CONCLUSIONS: Our study indicates that OspA-specific HuMabs can prevent the transmission of Borrelia and that administration of these antibodies could be employed as preexposure prophylaxis for Lyme disease.
BACKGROUND: Tick transmission of Borrelia spirochetes to humans results in significant morbidity from Lyme disease worldwide. Serum concentrations of antibodies against outer surface protein A (OspA) were shown to correlate with protection from infection with Borrelia burgdorferi, the primary cause of Lyme disease in the United States. METHODS:Mice transgenic for human immunoglobulin genes were immunized with OspA from B. burgdorferi to generate human monoclonal antibodies (HuMabs) against OspA. HuMabs were generated and tested in in vitro borreliacidal assays and animal protection assays. RESULTS: Nearly 100 unique OspA-specific HuMabs were generated, and 4 HuMabs (221-7, 857-2, 319-44, and 212-55) were selected as lead candidates on the basis of borreliacidal activity. HuMabs 319-44, 857-2, and 212-55 were borreliacidal against 1 or 2 Borrelia genospecies, whereas 221-7 was borreliacidal (half maximal inhibitory concentration, < 1 nM) against B. burgdorferi, Borrelia afzelii, and Borrelia garinii, the 3 main genospecies endemic in the United States, Europe, and Asia. All 4 HuMabs completely protected mice from infection at 10 mg/kg in a murine model of tick-mediated transmission of B. burgdorferi CONCLUSIONS: Our study indicates that OspA-specific HuMabs can prevent the transmission of Borrelia and that administration of these antibodies could be employed as preexposure prophylaxis for Lyme disease.
Authors: W T Golde; J Piesman; M C Dolan; M Kramer; P Hauser; Y Lobet; C Capiau; P Desmons; P Voet; D Dearwester; J C Frantz Journal: Infect Immun Date: 1997-03 Impact factor: 3.441
Authors: Ian Livey; Maria O'Rourke; Andreas Traweger; Helga Savidis-Dacho; Brian A Crowe; P Noel Barrett; Xiaohua Yang; John J Dunn; Benjamin J Luft Journal: Clin Infect Dis Date: 2011-02 Impact factor: 9.079
Authors: Christoph A Diebolder; Frank J Beurskens; Rob N de Jong; Roman I Koning; Kristin Strumane; Margaret A Lindorfer; Marleen Voorhorst; Deniz Ugurlar; Sara Rosati; Albert J R Heck; Jan G J van de Winkel; Ian A Wilson; Abraham J Koster; Ronald P Taylor; Erica Ollmann Saphire; Dennis R Burton; Janine Schuurman; Piet Gros; Paul W H I Parren Journal: Science Date: 2014-03-14 Impact factor: 47.728
Authors: Yang Wang; Rianne Esquivel; Seleeke Flingai; Zachary A Schiller; Aurélie Kern; Sangya Agarwal; Jacqueline Chu; Ami Patel; Katherine Sullivan; Megan C Wise; Kate E Broderick; Linden Hu; David B Weiner; Mark S Klempner Journal: J Infect Dis Date: 2019-03-15 Impact factor: 5.226
Authors: Zachary A Schiller; Michael J Rudolph; Jacqueline R Toomey; Monir Ejemel; Alan LaRochelle; Simon A Davis; Havard S Lambert; Aurélie Kern; Amanda C Tardo; Colby A Souders; Eric Peterson; Rebecca D Cannon; Chandrashekar Ganesa; Frank Fazio; Nicholas J Mantis; Lisa A Cavacini; John Sullivan-Bolyai; Linden T Hu; Monica E Embers; Mark S Klempner; Yang Wang Journal: J Clin Invest Date: 2021-06-01 Impact factor: 14.808
Authors: Serena Giuntini; Matteo Stoppato; Maja Sedic; Monir Ejemel; Jessica R Pondish; Danielle Wisheart; Zachary A Schiller; William D Thomas; Eileen M Barry; Lisa A Cavacini; Mark S Klempner; Yang Wang Journal: Infect Immun Date: 2018-07-23 Impact factor: 3.441